Segment Information (Tables)

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Schedule of Segment Information

The following table is a summary of segment information for the three months ended March 31, 2025 and 2024 (in thousands):

	Three Months Ended March 31,
	2025			2024
Operating Expenses
Late-stage development	$	28,097		$	27,292
Early-stage, preclinical and discovery programs		9,778			6,520
R&D personnel related		14,874			10,680
Research and development software, facilities and other strategic support		4,425			3,221
Other operational infrastructure and advisory support		7,121			4,700
Stock-based compensation expense		10,008			9,393
Depreciation expense		640			600
Interest income		(2,952	)		(4,057	)
Other expense, net		(5	)		(1	)
Segment net loss and consolidated net loss	$	71,986		$	58,348